MBrace
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $85M
Overview
An oncology biotech developing next-generation antibody-drug conjugates (ADCs) for targeted cancer therapy.
Oncology
Technology Platform
Platform for developing next-generation ADCs through novel target discovery and proprietary linker-payload technology.
Funding History
1Total raised:$85M
PIPE$85M
Opportunities
The ADC market is growing rapidly, offering blockbuster potential for novel agents with improved efficacy and safety profiles in oncology.
Risk Factors
Clinical risk of insufficient efficacy or unexpected toxicities, which have historically plagued ADC development, alongside intense competition.
Competitive Landscape
Enters a crowded but lucrative ADC field, competing with major pharma companies and numerous biotechs on technological differentiation.